Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.41 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.41 |
| ▸ | RELA | Q04206 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.40 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.40 |
| ▸ | CASP3 | P42574 | 1/20 | 0.40 |
| ▸ | KDR | P35968 | 1/20 | 0.40 |
| ▸ | AURKA | O14965 | 3/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.38 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.38 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.38 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.38 |
| ▸ | GSK3A | P49840 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18170636 | 0.87 | NPC1 (0.46) | KMT2ANPC1RAB9ASMN1; SMN2CASP3 | |
| SCHEMBL18170590 | 0.84 | CYP11B1 (0.57) | NPC1RAB9ACYP11B1CYP11B2CASP3 | |
| SCHEMBL18170896 | 0.82 | CASP3 (0.41) | KMT2ANPC1RAB9AMAPTSMN1; SMN2 | |
| SCHEMBL18170461 | 0.80 | MEN1 (0.52) | KMT2ANPC1RAB9ACYP11B1CYP11B2 | |
| SCHEMBL18170959 | 0.78 | TYK2 (0.50) | CASP3KDRKDM4EALDH1A1 | |
| SCHEMBL18170783 | 0.78 | KCNMA1 (0.51) | KMT2ATP53SMN1; SMN2CASP3KDR | |
| SCHEMBL18170549 | 0.78 | KDR (0.53) | KMT2ANPC1RAB9ACASP3KDR | |
| SCHEMBL18171017 | 0.77 | MEN1 (0.48) | KMT2ANPC1RAB9ASMN1; SMN2CASP3 | |
| SCHEMBL18170467 | 0.77 | MEN1 (0.48) | KMT2ANPC1RAB9ASMN1; SMN2CASP3 | |
| SCHEMBL18170550 | 0.77 | CASP3 (0.47) | KMT2ANPC1RAB9ASMN1; SMN2CASP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9856216-B2 | Compounds as TNIK, IKKε and TBK1 inhibitors and pharmaceutical composition comprising same | GREEN CROSS CORPORATION (KR) | 2018-01-02 | — | — | US | claimed |
| US-20160311772-A1 | COMPOUNDS AS TNIK, IKKEPSILON AND TBK1 INHIBITORS AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | GREEN CROSS CORPORATION (KR) | 2016-10-27 | — | — | US | claimed |
| US-9856216-B2 | Compounds as TNIK, IKKε and TBK1 inhibitors and pharmaceutical composition comprising same | GREEN CROSS CORPORATION (KR) | 2018-01-02 | — | — | US | disclosed |
| US-20160311772-A1 | COMPOUNDS AS TNIK, IKKEPSILON AND TBK1 INHIBITORS AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | GREEN CROSS CORPORATION (KR) | 2016-10-27 | — | — | US | disclosed |
| US-20160311772-A1 | COMPOUNDS AS TNIK, IKKEPSILON AND TBK1 INHIBITORS AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | GREEN CROSS CORPORATION (KR) | 2016-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160311772-A1 | COMPOUNDS AS TNIK, IKKEPSILON AND TBK1 INHIBITORS AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | TNIK, TNK1, NFKBIA | KMT2A 1369/4885NPC1 2005/4885RAB9A 2823/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.